Last updated: 11/07/2018 05:09:40
Safety and efficacy study of albiglutide in type 2 diabetes
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared With Placebo in Subjects With Type 2 Diabetes Mellitus
Trial description: The purpose of this study is to determine whether albiglutide is effective in the treament of patients with type 2 diabetes.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Change from Baseline (BL) in glycosylated hemoglobin (HbA1c) at Week 52
Timeframe: Baseline and Week 52
Secondary outcomes:
Change from Baseline in HbA1c at Weeks 104 and 156
Timeframe: Baseline and Weeks 104 and 156
Time to hyperglycemia rescue
Timeframe: From the start of study medication until the end of the treatment (up to Week 156)
Change from Baseline in fasting plasma glucose (FPG) at Week 52
Timeframe: Baseline and Week 52
Change from Baseline in fasting plasma glucose (FPG) at Week 156
Timeframe: Baseline and Week 156
Number of participants who achieved clinically meaningful HbA1c response levels of <6.5%, <7%, and <7.5% at Week 52
Timeframe: Week 52
Number of participants who achieved clinically meaningful HbA1c response levels of <6.5%, <7%, and <7.5% at Week 156
Timeframe: Week 156
Change from Baseline in body weight at Week 52
Timeframe: Baseline and Week 52
Change from Baseline in body weight at Week 156
Timeframe: Baseline and Week 156
Change From Baseline in Postprandial Blood Glucose Profile Parameter-4 hour c-peptide AUC
Timeframe: Baseline and Week 52
Change From Baseline in Postprandial Blood Glucose Profile Parameter- 4 hour Blood Glucose AUC
Timeframe: Baseline and Week 52
Change From Baseline in Postprandial Blood Glucose Profile Parameters-4 hour insulin AUC and 4 hour proinsulin AUC
Timeframe: Baseline and Week 52
Albiglutide plasma concentration at Weeks 8 and 24
Timeframe: Weeks 8 and 24
Interventions:
Enrollment:
309
Primary completion date:
2011-17-11
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Nauck M, Stewart M, Perkins C, Jones-Leone A, Yang F, Perry C, Reinhardt R, Rendel Marc.HARMONY 2 PRIMARY ENDPOINT PUBLICATION THIRD RESUBMISSION: Week 52 Primary Endpoint Results: Once Weekly (QW) Glucagon-Like Peptide-1 Receptor Agonist Albiglutide (Albi) Monotherapy For Patients (Pts) With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Diet and Exercise .Diabetologia.2016;59:266-274.
- type 2 diabetes
- BMI 20-45kg/m2 inclusive
- females who are pregnant, lactating, or <6 weeks post-partum
- CHF NYHA class III-IV
Inclusion and exclusion criteria
Inclusion criteria:
- type 2 diabetes
- BMI 20-45kg/m2 inclusive
Exclusion criteria:
- females who are pregnant, lactating, or <6 weeks post-partum
- CHF NYHA class III-IV
Trial location(s)
Location
GSK Investigational Site
West Valley City, Utah, United States, 84120
Status
Study Complete
Location
GSK Investigational Site
Fort Worth, Texas, United States, 76104
Status
Study Complete
Location
GSK Investigational Site
Greenville, South Carolina, United States, 29601
Status
Terminated/Withdrawn
Location
GSK Investigational Site
West Hills, California, United States, 91307
Status
Study Complete
Location
GSK Investigational Site
Canal Fulton, Ohio, United States, 44614
Status
Study Complete
Location
GSK Investigational Site
Pembroke Pines, Florida, United States, 33027
Status
Study Complete
Location
GSK Investigational Site
Kettering, Ohio, United States, 45429
Status
Terminated/Withdrawn
Location
GSK Investigational Site
La Porte, Indiana, United States, 46350
Status
Terminated/Withdrawn
Location
GSK Investigational Site
San Diego, California, United States, 92117
Status
Study Complete
Location
GSK Investigational Site
Sugarland, Texas, United States, 77479
Status
Study Complete
Location
GSK Investigational Site
Lewisville, Texas, United States, 75067
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Clarksville, Tennessee, United States, 37043
Status
Study Complete
Location
GSK Investigational Site
Harrisburg, Pennsylvania, United States, 17112
Status
Study Complete
Location
GSK Investigational Site
Atlanta, Georgia, United States, 30308
Status
Study Complete
Location
GSK Investigational Site
La Grange, Illinois, United States, 60525
Status
Study Complete
Location
GSK Investigational Site
Thornville, Ohio, United States, 43076
Status
Study Complete
Location
GSK Investigational Site
Taylors, South Carolina, United States, 29687
Status
Study Complete
Location
GSK Investigational Site
Idaho Falls, Idaho, United States, 83404
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Vista, California, United States, 92083
Status
Study Complete
Location
GSK Investigational Site
Gilbert, Arizona, United States, 85295
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Selah, Washington, United States, 98942
Status
Study Complete
Location
GSK Investigational Site
Crossville, Tennessee, United States, 38555
Status
Terminated/Withdrawn
Location
GSK Investigational Site
San Antonio, Texas, United States, 78224
Status
Study Complete
Location
GSK Investigational Site
Overland Park, Kansas, United States, 66211
Status
Study Complete
Location
GSK Investigational Site
Corpus Christi, Texas, United States, 78414
Status
Terminated/Withdrawn
Location
GSK Investigational Site
South Burlington, Vermont, United States, 05403
Status
Study Complete
Location
GSK Investigational Site
South Bend, Indiana, United States, 46614
Status
Study Complete
Location
GSK Investigational Site
Bay City, Michigan, United States, 48708
Status
Study Complete
Location
GSK Investigational Site
San Diego, California, United States, 92128
Status
Study Complete
Location
GSK Investigational Site
Omaha, Nebraska, United States, 68124
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Shreveport, Louisiana, United States, 71101
Status
Study Complete
Location
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53226
Status
Terminated/Withdrawn
Location
GSK Investigational Site
New Britain, Connecticut, United States, 06050
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Naperville, Illinois, United States, 60564
Status
Study Complete
Location
GSK Investigational Site
Interlochen, Michigan, United States, 49643
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Fayetteville, North Carolina, United States, 28304
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Greenville, South Carolina, United States, 29615
Status
Study Complete
Location
GSK Investigational Site
San Antonio, Texas, United States, 78229-4801
Status
Study Complete
Location
GSK Investigational Site
Zanesville, Ohio, United States, 43701
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Tullahoma, Tennessee, United States, 37388
Status
Terminated/Withdrawn
Location
GSK Investigational Site
San Diego, California, United States, 92120
Status
Study Complete
Location
GSK Investigational Site
Downington, Pennsylvania, United States, 19335
Status
Study Complete
Location
GSK Investigational Site
Chula Vista, California, United States, 91910
Status
Study Complete
Location
GSK Investigational Site
Tucson, Arizona, United States, 85745
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Oxon Hill, Maryland, United States, 20745
Status
Study Complete
Location
GSK Investigational Site
Great Falls, Montana, United States, 59405
Status
Study Complete
Location
GSK Investigational Site
San Antonio, Texas, United States, 78218
Status
Study Complete
Location
GSK Investigational Site
Richland, Washington, United States, 99352
Status
Study Complete
Location
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73103
Status
Study Complete
Location
GSK Investigational Site
Haverhill, Massachusetts, United States, 01830
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90025
Status
Study Complete
Location
GSK Investigational Site
Hallandale Beach, Florida, United States, 33009
Status
Study Complete
Location
GSK Investigational Site
Sugar Land, Texas, United States, 77479
Status
Study Complete
Location
GSK Investigational Site
Jonesboro, Arkansas, United States, 72401
Status
Study Complete
Location
GSK Investigational Site
Lenoir, North Carolina, United States, 28645
Status
Study Complete
Location
GSK Investigational Site
Maumee, Ohio, United States, 43537-9402
Status
Study Complete
Location
GSK Investigational Site
Arkansas City, Kansas, United States, 67005
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Torrance, California, United States, 90503
Status
Study Complete
Location
GSK Investigational Site
Uniontown, Pennsylvania, United States, 15401
Status
Study Complete
Location
GSK Investigational Site
Springfield, Missouri, United States, 65807
Status
Study Complete
Location
GSK Investigational Site
Fort Lauderdale, Florida, United States, 33316
Status
Study Complete
Location
GSK Investigational Site
Atlanta, Georgia, United States, 30338
Status
Study Complete
Location
GSK Investigational Site
Lauderdale Lakes, Florida, United States, 33319
Status
Study Complete
Location
GSK Investigational Site
Picayune, Mississippi, United States, 39466
Status
Study Complete
Location
GSK Investigational Site
Walnut Creek, California, United States, 94598
Status
Study Complete
Location
GSK Investigational Site
Spokane, Washington, United States, 99216
Status
Study Complete
Location
GSK Investigational Site
Dearborn, Michigan, United States, 48124
Status
Study Complete
Location
GSK Investigational Site
San Antonio, Texas, United States, 78215
Status
Study Complete
Location
GSK Investigational Site
Green Valley, Arizona, United States, 85614
Status
Study Complete
Location
GSK Investigational Site
Morehead City, North Carolina, United States, 28557
Status
Study Complete
Location
GSK Investigational Site
Shelby, North Carolina, United States, 28150
Status
Study Complete
Location
GSK Investigational Site
Pasadena, California, United States, 91105
Status
Study Complete
Location
GSK Investigational Site
San Diego, California, United States, 92177
Status
Study Complete
Location
GSK Investigational Site
Covington, Louisiana, United States, 70433
Status
Study Complete
Location
GSK Investigational Site
Palm Desert, California, United States, 92260
Status
Study Complete
Location
GSK Investigational Site
St Clair Shores, Michigan, United States, 48081
Status
Study Complete
Location
GSK Investigational Site
Houston, Texas, United States, 77030
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Kalamazoo, Michigan, United States, 49048
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Santa Ana, California, United States, 92701
Status
Study Complete
Location
GSK Investigational Site
Rolling Fork, Mississippi, United States, 39159
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Murrells Inlet, South Carolina, United States, 29576
Status
Study Complete
Location
GSK Investigational Site
Kalamazoo, Michigan, United States, 49009
Status
Study Complete
Location
GSK Investigational Site
Simpsonville, South Carolina, United States, 29681
Status
Study Complete
Location
GSK Investigational Site
Manassas, Virginia, United States, 20110
Status
Study Complete
Location
GSK Investigational Site
Blue Ridge, Georgia, United States, 30513
Status
Study Complete
Location
GSK Investigational Site
Chesterfield, Missouri, United States, 63017
Status
Study Complete
Location
GSK Investigational Site
Plantation, Florida, United States, 33317
Status
Study Complete
Location
GSK Investigational Site
North Myrtle Beach, South Carolina, United States, 29582
Status
Study Complete
Location
GSK Investigational Site
Deerfield Beach, Florida, United States, 33442
Status
Study Complete
Location
GSK Investigational Site
Iowa City, Iowa, United States, 52243
Status
Terminated/Withdrawn
Location
GSK Investigational Site
East Providence, Rhode Island, United States, 02914
Status
Study Complete
Location
GSK Investigational Site
Dayton, Ohio, United States, 45432
Status
Terminated/Withdrawn
Location
GSK Investigational Site
West Jordan, Utah, United States, 84088
Status
Study Complete
Location
GSK Investigational Site
Baltimore, Maryland, United States, 21237-3998
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Los Alamitos, California, United States, 90720
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Greer, South Carolina, United States, 29651
Status
Study Complete
Location
GSK Investigational Site
Tijuana, Baja California Norte, Mexico, 22010
Status
Study Complete
Location
GSK Investigational Site
Lansdale, Pennsylvania, United States, 19446
Status
Study Complete
Location
GSK Investigational Site
St. Louis, Missouri, United States, 63141
Status
Study Complete
Location
GSK Investigational Site
Suffolk, Virginia, United States, 23434
Status
Study Complete
Location
GSK Investigational Site
Greensboro, North Carolina, United States, 27455
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Columbia, South Carolina, United States, 29201
Status
Study Complete
Location
GSK Investigational Site
Orlando, Florida, United States, 32822
Status
Study Complete
Location
GSK Investigational Site
Honolulu, Hawaii, United States, 96814
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90017
Status
Study Complete
Location
GSK Investigational Site
West Palm Beach, Florida, United States, 33401
Status
Study Complete
Location
GSK Investigational Site
Clearwater, Florida, United States, 33756
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Decatur, Georgia, United States, 30032
Status
Study Complete
Location
GSK Investigational Site
Birmingham, Alabama, United States, 35235
Status
Study Complete
Location
GSK Investigational Site
Nashville, Tennessee, United States, 37203
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Mint Hill, North Carolina, United States, 28227
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Asheville, North Carolina, United States, 28803
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Chandler, Arizona, United States, 85225
Status
Study Complete
Location
GSK Investigational Site
Benzonia, Michigan, United States, 49616
Status
Study Complete
Location
GSK Investigational Site
Tarzana, California, United States, 91356
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Elizabeth, New Jersey, United States, 07202
Status
Study Complete
Location
GSK Investigational Site
Haddon Heights, New Jersey, United States, 08035
Status
Study Complete
Location
GSK Investigational Site
Calabash, North Carolina, United States, 28467
Status
Study Complete
Location
GSK Investigational Site
Tucker, Georgia, United States, 30084
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Paducah, Kentucky, United States, 42003
Status
Study Complete
Location
GSK Investigational Site
Stratford, New Jersey, United States, 08084
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Tipton, Pennsylvania, United States, 16684
Status
Study Complete
Location
GSK Investigational Site
Broken Bow, Nebraska, United States, 68822
Status
Terminated/Withdrawn
Location
GSK Investigational Site
St. Cloud, Florida, United States, 34769
Status
Study Complete
Location
GSK Investigational Site
Crescent Springs, Kentucky, United States, 41017
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Peoria, Illinois, United States, 61602
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Snellville, Georgia, United States, 30078
Status
Study Complete
Location
GSK Investigational Site
Tabor City, North Carolina, United States, 28463
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Chicago, Illinois, United States, 60607
Status
Study Complete
Location
GSK Investigational Site
San Antonio, Texas, United States, 78258
Status
Study Complete
Location
GSK Investigational Site
Houston, Texas, United States, 77074
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Columbus, Georgia, United States, 31904
Status
Study Complete
Location
GSK Investigational Site
Lake Charles, Louisiana, United States, 70601
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Hialeah, Florida, United States, 33012
Status
Study Complete
Location
GSK Investigational Site
Cutler Bay, Florida, United States, 33189
Status
Study Complete
Location
GSK Investigational Site
Long Beach, California, United States, 90806
Status
Study Complete
Location
GSK Investigational Site
Morelia, Michoacán, Mexico, C.P. 58249
Status
Study Complete
Location
GSK Investigational Site
Foothill Ranch, California, United States, 92610
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Pembroke Pines, Florida, United States, 33026
Status
Study Complete
Location
GSK Investigational Site
Searcy, Arkansas, United States, 72143
Status
Study Complete
Location
GSK Investigational Site
Hollywood, Florida, United States, 33023
Status
Study Complete
Location
GSK Investigational Site
Columbia, Tennessee, United States, 38401
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Johnson City, Tennessee, United States, 37604
Status
Study Complete
Location
GSK Investigational Site
Las Vegas, Nevada, United States, 89106
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Kansas City, Missouri, United States, 64111
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Madisonville, Kentucky, United States, 42431
Status
Study Complete
Location
GSK Investigational Site
Marianna, Florida, United States, 32446
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Phoenix, Arizona, United States, 85051
Status
Study Complete
Location
GSK Investigational Site
Council Bluffs, Iowa, United States, 51501
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90022
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Little Rock, Arkansas, United States, 72205
Status
Study Complete
Location
GSK Investigational Site
Honolulu, Hawaii, United States, 96813
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Sacramento, California, United States, 95825
Status
Study Complete
Location
GSK Investigational Site
Carmichael, California, United States, 95608
Status
Study Complete
Location
GSK Investigational Site
Atlanta, Georgia, United States, 30312
Status
Study Complete
Location
GSK Investigational Site
Las Vegas, Nevada, United States, 89103
Status
Study Complete
Location
GSK Investigational Site
Indianapolis, Indiana, United States, 46254
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Berlin, New Jersey, United States, 08009
Status
Study Complete
Location
GSK Investigational Site
Salt Lake City, Utah, United States, 84120
Status
Study Complete
Location
GSK Investigational Site
Satna Monica, California, United States, 90404
Status
Study Complete
Location
GSK Investigational Site
Arvada, Colorado, United States, 80005
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Middletown, Delaware, United States, 19709
Status
Study Complete
Location
GSK Investigational Site
Las Vegas, Nevada, United States, 89128
Status
Study Complete
Location
GSK Investigational Site
Evergreen Park, Illinois, United States, 60805
Status
Study Complete
Location
GSK Investigational Site
Bensalem, Pennsylvania, United States, 19020
Status
Study Complete
Location
GSK Investigational Site
Riverside, California, United States, 92506
Status
Study Complete
Location
GSK Investigational Site
Melrose Park, Pennsylvania, United States, 19027
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Salt Lake City, Utah, United States, 84102
Status
Study Complete
Location
GSK Investigational Site
Evansville, Indiana, United States, 47714
Status
Study Complete
Location
GSK Investigational Site
Hainesport, New Jersey, United States, 08036
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Savannah, Georgia, United States, 31419
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Lexington, Kentucky, United States, 40504
Status
Study Complete
Location
GSK Investigational Site
Midland, Texas, United States, 79705
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Alabaster, Alabama, United States, 35007
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Hot Springs, Arkansas, United States, 71913
Status
Study Complete
Location
GSK Investigational Site
Ormond Beach, Florida, United States, 32174
Status
Study Complete
Location
GSK Investigational Site
McKenzie, Tennessee, United States, 38201
Status
Study Complete
Location
GSK Investigational Site
Huntington Beach, California, United States, 92646
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Delray Beach, Florida, United States, 33445
Status
Study Complete
Location
GSK Investigational Site
Hickory, North Carolina, United States, 28601
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Chadbourn, North Carolina, United States, 28431
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Irvine, California, United States, 92618
Status
Study Complete
Location
GSK Investigational Site
Lewisburg, West Virginia, United States, 24901
Status
Study Complete
Location
GSK Investigational Site
Salt Lake City, Utah, United States, 84107
Status
Study Complete
Location
GSK Investigational Site
Huntington Beach, California, United States, 92648
Status
Study Complete
Location
GSK Investigational Site
Birmingham, Alabama, United States, 35242
Status
Study Complete
Location
GSK Investigational Site
Lakewood, California, United States, 90712
Status
Terminated/Withdrawn
Location
GSK Investigational Site
North Massapequa, New York, United States, 11758
Status
Study Complete
Location
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15243
Status
Study Complete
Location
GSK Investigational Site
Fresno, California, United States, 93720
Status
Study Complete
Location
GSK Investigational Site
Jefferson City, Missouri, United States, 65109
Status
Study Complete
Location
GSK Investigational Site
Omaha, Nebraska, United States, 68134
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Norfolk, Virginia, United States, 23502
Status
Study Complete
Location
GSK Investigational Site
Atlanta, Georgia, United States, 30342
Status
Study Complete
Location
GSK Investigational Site
Virgina Beach, Virginia, United States, 23455
Status
Study Complete
Location
GSK Investigational Site
Bristol, Tennessee, United States, 37620
Status
Study Complete
Location
GSK Investigational Site
Arlington, Texas, United States, 76012
Status
Study Complete
Location
GSK Investigational Site
Indio, California, United States, 92201
Status
Study Complete
Location
GSK Investigational Site
Burlington, North Carolina, United States, 27215
Status
Study Complete
Location
GSK Investigational Site
Savannah, Georgia, United States, 31406
Status
Study Complete
Location
GSK Investigational Site
Spring Valley, California, United States, 91978
Status
Study Complete
Location
GSK Investigational Site
Mission Viejo, California, United States, 92691
Status
Study Complete
Location
GSK Investigational Site
Victorville, California, United States, 92395
Status
Study Complete
Location
GSK Investigational Site
Northridge, California, United States, 91325
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Shreveport, Louisiana, United States, 71115
Status
Study Complete
Location
GSK Investigational Site
Panama City, Florida, United States, 32401
Status
Study Complete
Location
GSK Investigational Site
Houston, Texas, United States, 77058
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Weber City, Virginia, United States, 24290
Status
Study Complete
Location
GSK Investigational Site
Deer Park, Texas, United States, 77536
Status
Study Complete
Location
GSK Investigational Site
Bull Shoals, Arkansas, United States, 72619
Status
Study Complete
Location
GSK Investigational Site
Orangeburg, South Carolina, United States, 29115
Status
Study Complete
Location
GSK Investigational Site
Lincoln, Nebraska, United States, 68516
Status
Study Complete
Location
GSK Investigational Site
West Plains, Missouri, United States, 65775
Status
Study Complete
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2011-17-11
Actual study completion date
2013-22-02
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website